drugset / Trial / NCT00553475

Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy

NCT00553475

Phase 3 Completed 314 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of pregabalin at 300 mg/day and 600 mg/day (BID) in patients with painful diabetic peripheral neuropathy.

Timeline

Start
2007-10
Primary completion
2009-03
Completion
2009-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 300 mg Oral
Subject Pregabalin Small molecule 600 mg Oral

Indications